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Introduction
The retina is referred to as an “immune-privileged” tissue, where immune homeostasis is maintained through 
hematopoietic immune cells, such as microglia, and immune-competent tissue-resident cells, such as the ret-
inal pigment epithelium (RPE) (1). The RPE is highly differentiated and considered a postmitotic single-cell 
layer performing a host of  functions critical to retinal homeostasis, including maintenance of  the visual cycle 
and photoreceptor phagocytosis (2). RPE cells are highly metabolically active while providing critical met-
abolic support through, for example, directional transport of  glucose and lactate to fuel the outer retina and 
particularly photoreceptors (3). Studies of  cultured RPE cells show that they can derive energy from glucose 
by aerobic glycolysis or oxidative phosphorylation (OXPHOS), depending on culture conditions. Defects in 
RPE metabolic and mitochondrial function, associated with low-grade inflammation or age-related decline, 
are associated with retinal degenerative diseases, including age-related macular degeneration (AMD) (4). 
However, the causal link between RPE metabolic alterations and retinal function and disease remains unclear.
Immune cells with different functions use several metabolic pathways to generate adequate levels of energy 
stores to support survival and to produce numerous biosynthetic intermediates to enable cellular growth and pro-
liferation (5). Understanding how immune-competent tissue-resident cells, like RPE, manage energy consump-
tion to potentially support outer retinal function maintenance is crucial, yet unknown. RPE cells utilize reductive 
carboxylation (6) to support redox homeostasis. This in turn is reinforced by the disproportionate damage to 
mitochondrial DNA (mtDNA) in the RPE of individuals with AMD. Furthermore, the role of lipids, which 
accumulate in the macula, and their oxidation, has emerged as an important factor in AMD development (7).
It remains unresolved how retinal pigment epithelial cell metabolism is regulated following 
immune activation to maintain retinal homeostasis and retinal function. We exposed retinal 
pigment epithelium (RPE) to several stress signals, particularly Toll-like receptor stimulation, and 
uncovered an ability of RPE to adapt their metabolic preference on aerobic glycolysis or oxidative 
glucose metabolism in response to different immune stimuli. We have identified interleukin-33 
(IL-33) as a key metabolic checkpoint that antagonizes the Warburg effect to ensure the functional 
stability of the RPE. The identification of IL-33 as a key regulator of mitochondrial metabolism 
suggests roles for the cytokine that go beyond its extracellular “alarmin” activities. IL-33 exerts 
control over mitochondrial respiration in RPE by facilitating oxidative pyruvate catabolism. We 
have also revealed that in the absence of IL-33, mitochondrial function declined and resultant 
bioenergetic switching was aligned with altered mitochondrial morphology. Our data not only 
shed new light on the molecular pathway of activation of mitochondrial respiration in RPE in 
response to immune stressors but also uncover a potentially novel role of nuclear intrinsic IL-33 as 
a metabolic checkpoint regulator.
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IL-33, a member of the IL-1 family, is a type 2 cytokine that is constitutively expressed in the inner retina, 
RPE, and choroid (8), as well as in epithelial cells, endothelial cells, and fibroblasts (9). IL-33 functions as an 
“alarmin” molecule released from barrier cells following cellular damage (10). IL-33 is a pleiotropic cytokine 
with effects that are pro- or antiinflammatory depending on disease or cell context (11). This is reflected by major 
roles in infection, allergic responses, metabolic homeostasis, and cancer (12–14). Growing evidence suggests that 
IL-33 plays an important role in systemic metabolic diseases, like type 2 diabetes (15), and cardiac disease (16).
We have previously shown that TLR ligands (TLR-3, -4) induce upregulation of  IL-33 in RPE cells with-
out cell death. We also demonstrated a protective role for IL-33 in regulating ocular tissue responses to pro-
mote wound healing (8). Recent exploitation of  the cytoplasmic hybrid technique for representative mtDNA 
haplotypes of  AMD populations revealed alterations in IL-33 expression and altered bioenergetics (17). This, 
coupled with novel epigenetic roles for IL-33 as shown in the maintenance of  mitochondrial function in adi-
pose tissue (18), led us to investigate whether IL-33 acts as an intracellular checkpoint for RPE metabolism 
regulation. Here, we characterize RPE metabolic reprogramming in response to TLR ligation. We provide 
evidence that immune-mediated signals drive differential bioenergetic sourcing within the RPE, leading to a 
specific nuclear signature of  IL-33 expression that maintains mitochondrial health and allows cells to respond 
and deliver energy intermediates required for RPE function.
Results
RPE has a differential metabolic response to varying TLR agonists. The bioenergetic response of  RPE cells to 
potentially harmful signals (through TLR stimulation) was investigated to ascertain the response and ability 
to maintain function under acute immune stress. We employed a Seahorse XF Analyzer (Agilent Technol-
ogies) to determine whether TLR activation altered RPE cellular metabolism.
Stimulation of  RPE by LPS, a potent ligand of  TLR4, promoted a substantial increase (1.5-fold) in the 
extracellular acidification rate (ECAR) relative to resting controls (Figure 1A) accompanied by a decrease in 
oxygen consumption rate (OCR) in human RPE cells (ARPE-19) (Figure 1B). These data imply increased 
aerobic glycolysis in LPS-stimulated ARPE-19 cells (Figure 1C), and this was supported by an increase in 
glucose consumption (Figure 1D). In contrast to LPS, stimulation of  RPE by poly(I:C), a ligand for TLR3, for 
6 hours led to increased aerobic metabolism in TLR3-activated RPE (Figure 1C) accompanied by increased 
glycolytic reserve after oligomycin (Supplemental Figure 1, A and B; supplemental material available online 
with this article; https://doi.org/10.1172/jci.insight.129429DS1).
To confirm the differential bioenergetic adaptations of the RPE to TLR stimulation, abundance of intra-
cellular metabolites stable isotope tracer analysis (SITA) was assessed with [U-13C]-glucose (schematic in Sup-
plemental Figure 2A). SITA indicated that treatment with both LPS and poly(I:C) increased the incorporation 
of C13 glucose into glyceraldehyde-3-phosphate (G3P) (Supplemental Figure 2B), pyruvate, and lactate (Figure 
1E), indicating increased glycolytic flux. Both treatments led to an increased incorporation of C13 glucose into 
TCA metabolites citrate and fumarate (Figure 1E) and succinate (Supplemental Figure 2C), aspartate (Sup-
plemental Figure 2E), and glutamate (Supplemental Figure 2G). The increased labeled succinate and aspar-
tate observed were attributed to an increase in the M+2 mass isotopologs (Supplemental Figure 2, D and F). 
Poly(I:C) treatment increased M+4 glutamate abundance (Supplemental Figure 2H), indicative of TCA cycling. 
Incorporation into the TCA intermediates was more pronounced with poly(I:C) treatment than LPS, confirming 
increased mitochondrial activity. Furthermore, the relative abundance of unlabeled C12 intermediates of fuma-
rate, succinate, aspartate, and glutamate substantially increased with poly(I:C) treatment, suggesting other fuels 
may contribute to these metabolite pools (Figure 1E, Supplemental Figure 2C, and Supplemental Figure 2G).
Our data indicated increased glycolysis in LPS-stimulated ARPE-19 cells (Figure 1C), and this was 
supported by an increase in glucose consumption (Figure 1D). We further demonstrated that LPS, but not 
poly(I:C), decreased the ATP/ADP ratio in ARPE-19 cells (Figure 1F), indicating a switch away from mito-
chondrial metabolism. We also found that there were no significant alterations to ATP turnover in these cells 
following LPS treatment for 24 hours (Figure 1G).
In addition to glucose-derived carbon entering the TCA cycle, we investigated how fatty acid metabolism 
was affected by TLR signaling. First, we measured malonyl CoA levels in treated cells to assess fatty acid synthe-
sis. We found that poly(I:C) stimulation led to a reduction of malonyl CoA, whereas LPS stimulation increased 
malonyl CoA levels (Figure 1H). We explored alterations to fatty acid oxidation through a modified mitochon-
drial stress test, including the third injection of etomoxir. We found that in response to LPS, fatty acid oxidation 
was reduced in RPE cells, whereas with poly(I:C) treatment, fatty acid oxidation was increased (Figure 1I).
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Figure 1. RPE has a differential metabolic response to varying TLR agonists. (A) ECAR changes following injection of LPS (1 μg/mL) or poly(I:C) (10 μg/mL) to 
ARPE-19 (n = 3). (B) OCR following injection of LPS or poly(I:C) to ARPE-19 (n = 3). (C) Relative OCR/ECAR ratio following treatment with LPS (30 minutes) or 
poly(I:C) (6 hours) to ARPE-19 (n = 3). (D) ARPE-19 treated for 24 hours with LPS or poly(I:C); glucose concentrations are expressed as relative consumption (n = 3). 
(E) Uniformly labeled C13-glucose incorporation into ARPE-19 metabolites treated for 24 hours with LPS or poly(I:C); relative abundance of C13 and C12 including 
pyruvate, lactate citrate, and fumarate (n = 3). ATP/ADP ratio (F) and relative ATP levels (G) of ARPE-19 stimulated for 24 hours with either LPS or poly(I:C) (n = 4). 
(H) Relative levels of malonyl CoA detected in whole cell lysates of ARPE-19 stimulated with either LPS or poly(I:C) for 24 hours (n = 3). (I) Modified mitochondrial 
stress test including a third injection of etomoxir (3 μg/mL) of ARPE-19 stimulated with either 30 minutes LPS or 6 hours poly(I:C) (n = 3). (J) ARPE-19 treated 
for 24 hours with LPS or poly(I:C); RNA was extracted and converted to cDNA; RT-PCR was used to determine the relative gene expression of targets involved in 
glycolysis or the TCA cycle (n = 3). GLUT1, glucose transporter 1; PC, pyruvate carboxylase; PKM2, pyruvate kinase M2. (K) ARPE-19 treated with LPS or poly(I:C) 
for 24 hours; protein was extracted and immunoblot analysis was used to determine the expression of PKM2, GLUT1, and PC. (L) Quantification of immunoblots 
presented in K (n = 3). (M) ARPE-19 treated with LPS (1 μg/mL) for 30 minutes or poly(I:C) (10 μg/mL) for 24 hours; protein was extracted and immunoblot analysis 
was used to determine the phosphorylation of PDH. (N) Quantification of immunoblots presented in M (n = 3). Data are expressed as means ± SD from at least 
3 independent experiments. A–C and I represent the biological repeats from 3 independent experiments (n = 3); each biological repeat is the mean of 2 technical 
repeats (2 seahorse wells per experiment). One-way ANOVA with Dunnett’s multiple comparisons test; *P < 0.05, **P < 0.01, ***P < 0.001.
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Consistent with increased rates of  glycolysis, reverse transcription PCR (RT-PCR) analysis demonstrat-
ed greater expression of  glycolytic enzymes following LPS treatment (Figure 1J). Poly(I:C) treatment also 
increased expression of  glycolytic enzymes, GLUT1, and TCA enzymes (Figure 1J). To confirm that the 
changes of  gene expression were consistent with protein expression, immunoblotting was performed on 3 
targets with significant alterations following TLR stimulation, GLUT1, PKM2, and PC, yielding compara-
ble results (Figure 1, K and L).
Pyruvate dehydrogenase (PDH) is inactivated by the phosphorylation on a highly conserved serine res-
idue (Ser293) in the E1 subunit that inhibits activity (19), restricting carbon entry into the TCA cycle. Con-
sistent with the increased abundance of  pyruvate and lactate, we observed that LPS treatment increased the 
phosphorylation, and thus inactivation, of  PDH (Figure 1, M and N). Furthermore, inhibition of  upstream 
kinase 1 (PDK1) reversed the LPS-mediated effects on ECAR and OCR (Supplemental Figure 1, C–F). Col-
lectively, these data show that LPS stimulation of  RPE drives a rapid switch to aerobic glycolysis, whereas 
poly(I:C) stimulation increases oxidative glucose metabolism and TCA activity.
We next investigated the structural changes to mitochondria that occur under innate immune activa-
tion. Mitochondria are hubs of  metabolic activity, antiviral responses, and cell death cascades that continu-
ally remodel their structure to facilitate cell processes (20). Dynamic changes in mitochondrial remodeling 
are acutely responsive to changes in cell metabolism (21). Treatment with poly(I:C), but not LPS, increased 
mitochondrial size relative to unstimulated controls (Supplemental Figure 3, A and B). Additionally, there 
was shift in mitochondrial morphologies, with decreased fragmented mitochondria, and an increase in long 
and short tubular mitochondria observed with TLR stimulation (Supplemental Figure 3F).
Finally, we investigated whether the metabolic changes we observed were applicable to other RPE cells 
and not unique to this immortalized RPE cell line. We performed these experiments on primary murine 
RPE. Similar results were observed (Supplemental Figure 1, G–I). To determine whether the metabolic 
changes observed in RPE were cell specific, other TLR-expressing cells within the retina (human Müller 
glia and murine bone marrow–derived mast cells, BMMCs) were used as comparators. We observed a com-
parable metabolic response in Müller glia, whereas BMMCs increased their aerobic glycolysis in response 
to both agonists (Supplemental Figure 1, J–M).
Alternate bioenergetic profiles are regulated by AMPK. Like immune cells (22), we hypothesized that in the 
RPE, TLR-induced metabolic responses are governed by AMPK activation status. ARPE-19 cells were cul-
tured in the presence or absence of  poly(I:C) or LPS at a range of  time points, from 30 minutes to 24 hours. 
Treatment with poly(I:C) had a maximal effect at 24 hours, upregulating the activity of  AMPK, demonstrat-
ed by measuring phosphorylation of  its downstream target, acetyl-CoA carboxylase (ACC) (Figure 2, A and 
C). Stimulation with LPS reduced the phosphorylation of  both AMPK and ACC observed at 30 minutes 
(Figure 2, B and C), supporting the metabolic changes shown in Figure 1, A and B.
Confirming its role as a key metabolic regulator, we found that pharmacological activation and inhi-
bition of  AMPK had opposing effects on RPE metabolism (Figure 2D and Supplemental Figure 4). The 
increase in OCR/ECAR with AICAR treatment supported the hypothesis that AMPK inhibits aerobic gly-
colysis (23). Further, we demonstrate that pharmacological activation of  AMPK attenuated the switch to 
aerobic glycolysis in response to LPS (Figure 2E).
The downstream PI3K/mTOR signaling pathway was also examined following TLR activation in RPE 
cells. Poly(I:C) treatment increased mTOR phosphorylation on Ser2448 of  the catalytic subunit and increased 
the expression of  mTOR substrate/surrogate p-70 S6 kinase (Figure 2, F and G). Stimulation with LPS 
upregulated the expression of  PI3K p110 (Figure 2, F and G). Downstream of PI3K, LPS treatment led to 
increased activity of  mTOR and p-70 S6 kinase (Figure 2, F and G).
These data demonstrate that the differential metabolic responses to TLR stimulation in the RPE are 
regulated by AMPK activity. The activation of  downstream signaling pathways supports the appropriate 
alterations of  RPE metabolism that facilitate effector functions under stress.
IL-33 increases mitochondrial metabolism in RPE. We have previously shown that TLR agonists induce the 
expression of  IL-33 in RPE cells, and this regulates cell responses and tissue homeostasis (8). By extrapolation 
from observations of  the metabolic changes associated with cytokine signaling in other immune cells (24), we 
hypothesized that activation of  RPE through the IL-33/ST2 axis also induces a metabolic change.
Alterations to the OCR/ECAR ratio were observed at 24 hours of  treatment of  ARPE-19 cells with 
IL-33 (Supplemental Figure 5, C and D), with no effect on RPE viability (Supplemental Figure 5, E and F). 
A mitochondrial stress test identified increases in oxidative metabolism following treatment, particularly 
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increases in spare respiratory capacity (Figure 3A and Supplemental Figure 5G). Glycolytic metabolism 
was also increased (Figure 3B and Supplemental Figure 5H). Primary murine RPE also increased aerobic 
metabolism in response to recombinant IL-33 (rhIL-33) treatment in an IL-1-receptor like 1–dependent 
(IL-1RL1–dependent) manner (Supplemental Figure 5J).
SITA with [U-13C]-glucose indicated increased C13 incorporation into G3P, pyruvate, and lactate 
pools with IL-33 treatment (Figure 3C). We also observed increased C13 incorporation into TCA metab-
olites fumarate, malate, succinate, and citrate (Figure 3D). The distribution of  the M+2 mass isotopolog 
was increased in the fumarate, malate, and succinate pools, following IL-33 treatment (Figure 3E). Glucose 
consumption was not significantly affected with IL-33 treatment (Figure 3F).
In addition to glucose-derived carbon entering the TCA cycle, we investigated how fatty acid metabolism 
was affected by IL-33 signaling. Consistent with the observed activation of  AMPK/inactivation of  ACC 
(Supplemental Figure 7, A–C), we observed an increase in fatty acid oxidation (Figure 3G). No changes were 
observed to the levels of  malonyl CoA with IL-33 treatment (Figure 3H).
RT-PCR analysis further supported an increase in gene expression of  glycolytic and TCA enzymes 
upon IL-33 stimulation (Figure 3I). Protein expression of  PKM2, GLUT1, and PC correlated with gene 
expression analysis (Figure 3, J and K).
Given the functional significance of  IL-33/ST2 signaling on mitochondrial capacity, we considered 
whether this pathway protects against oxidative damage to the RPE. To this end, H2O2 was used as an in 
vitro platform for inducing reactive oxygen species within the RPE (25). A dose-dependent relationship was 
Figure 2. Alternate bioenergetic profiles are regulated by the activity of AMPK. (A) ARPE-19 were treated with poly(I:C) (10 μg/mL) for 6 hours; pro-
tein was extracted and immunoblot analysis was used to determine the phosphorylation of AMPK and ACC. (B) ARPE-19 were treated with LPS (1 μg/
mL) for 30 minutes; protein was extracted and immunoblot analysis was used to determine the phosphorylation of AMPK and ACC. (C) Quantification 
of immunoblots presented in A and B (n = 3). (D) Relative basal OCR and ECAR of ARPE-19 treated for 30 minutes with either AMPK activator AICAR (1 
mM) or inhibitor compound C (40 μM) (n = 3). (E) Real-time changes in relative ECAR following injection of LPS (1 μg/mL) to ARPE-19 cells ± AICAR (1 mM) 
pretreatment for 30 minutes (n = 3). (F) ARPE-19 were treated with poly(I:C) (10 μg/mL) for 6 hours or LPS (1 μg/mL) for 1 hour; protein was extracted and 
immunoblot analysis was used to determine the activation of mTOR, p-70 s6 kinase, and PI3K. (G) Quantification of immunoblots presented in F (n = 3). 
(A, B, and F) Data are expressed as means ± SD from 3 independent blots. (D and E) Represent the biological repeats from 3 independent experiments (n = 
3); each biological repeat is the mean of 2 technical repeats (2 seahorse wells per experiment). (D) One-way ANOVA with Dunnett’s multiple comparisons 
test; *P < 0.05. (E) Unpaired Student’s t test; *P < 0.05, **P < 0.01.
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Figure 3. IL-33 increases bioenergetic demand. (A) Mitochondrial stress test from ARPE-19 treated with recombinant human IL-33 (rhIL-33) (100 ng/mL) 24 hours; 
XF injections were oligomycin (1 μM), carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) (0.5 μM), and rotenone/antimycin A (1 μM) (n = 3). (B) Glycol-
ysis stress test from ARPE-19 treated with rhIL-33 (100 ng/mL) 24 hours; XF injections were glucose (10 mM), oligomycin (1 μM), and 2-deoxyglucose (100 mM) (n = 
3). (C) Labeled C13-glucose incorporation into ARPE-19 glycolytic metabolites treated 24 hours with rhIL-33 (100 ng/mL) (n = 3). (D) Labeled C13-glucose incorpo-
ration into ARPE-19 TCA metabolites treated as in C. (E) Mass isotopomer distribution of C13-glucose–derived carbon into fumarate (M+2), succinate (M+2), and 
citrate (M+2) metabolite pools (n = 3). (F) ARPE-19 treated 24 hours with rhIL-33 (100 ng/mL); glucose concentrations were measured in the media prior/following 
treatment and expressed as relative consumption (n = 3). (G) Modified mitochondrial stress test including a third injection of etomoxir (3 μg/mL) of ARPE-19 cells 
treated 24 hours with rhIL-33 (100 ng/mL) (n = 3). (H) Relative levels of malonyl CoA detected in whole cell lysates of ARPE-19 (n = 3). ARPE-19 treated 24 hours 
with rhIL-33 (100ng/mL); (I) RT-PCR relative gene expression or (J and K) protein was extracted and immunoblot analysis was used to determine the expression of 
PKM2, GLUT1, and PC (n = 3). (L) ARPE-19 were treated with rhIL-33 (100 ng/mL) 12 hours before treatment with H2O2 (1 mM) 24 hours; LDH release was quantified 
in supernatants and expressed as relative to untreated control (n = 4). (M) ARPE-19 were treated with rhIL-33 (100 ng/mL) 12 hours before treatment with H2O2 (1 
mM) 24 hours; an MTT assay was used to determine cell viability and expressed as a percentage of untreated control (n = 4). (N) Modified mitochondrial stress test 
of ARPE-19 treated 24 hours with rhIL-33 (100 ng/mL); XF injections were H2O2 (1 mM), oligomycin (1 μM), FCCP (0.5 μM), and rotenone/antimycin A (1 μM) (n = 3). 
Data are expressed as means ± SD from at least 3 independent experiments. (A, B, and G) Represent the biological repeats from 3 independent experiments (n = 
3); each biological repeat is the mean of 2 technical repeats (2 seahorse wells/experiment). (N) Represents the biological repeats from 3 independent experiments 
(n = 3); each biological repeat is the mean of 2 technical repeats or single technical repeat (1 or 2 seahorse wells/experiment). One-way ANOVA, Dunnett’s multiple 
comparisons test; *P < 0.05,**P < 0.01, ***P < 0.005.
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observed between H2O2 concentration and cell viability (Supplemental Figure 6A). RPE cells treated with 
H2O2 for 24 hours exhibited reduced mitochondrial function and glycolytic capacity (Supplemental Figure 6, 
B and C). Pretreatment with IL-33 conferred some protection against H2O2-induced RPE dysfunction. This 
was indicated by reduced lactate dehydrogenase (LDH) release, an increase in cell viability to H2O2 alone 
(Figure 3, L and M), and maintenance of  mitochondrial OXPHOS both at 12 and 24 hours (Figure 3N and 
Supplemental Figure 6D). IL-33 was unable to rescue the H2O2-mediated defects in glycolytic metabolism 
with 12 hours of  treatment (Supplemental Figure 6E). Treatment with IL-33 for 24 hours had no significant 
initial “rescuing” effect to ECAR after H2O2, but at the greatest dose (100 ng/mL), ECAR levels were restored 
to controls by the end of  the assay (Supplemental Figure 6F). When IL-33 was added at the same time as 
H2O2, there was no protective effect (Supplemental Figure 6G), likely due to oxidation and consequent inacti-
vation of  IL-33 (26). We could not attribute the effect of  IL-33 treatment to expression changes in antioxidant 
enzymes or prosurvival proteins (Supplemental Figure 7, D–J). We observed that IL-33 induced a shift in 
mitochondrial morphology toward a more elongated phenotype and increased mitochondrial size (Supple-
mental Figure 8). Despite the observation that IL-33 increased PPARγ coactivator-1A (PGC1A), we found 
that IL-33 treatment had no significant effects on relative mtDNA expression levels (Supplemental Figure 8F), 
therefore suggesting that biogenesis may be unaffected (Supplemental Figure 8F).
IL-33 is essential for the maintenance of  mitochondrial respiration in RPE. Recent studies have determined a 
novel role for IL-33 in the maintenance of  mitochondrial respiration in beige and brown adipocytes (18). 
This coupled with the data we have shown thus far led us to further examine the effect of  IL-33 loss on 
RPE bioenergetics. To knock down IL-33 in ARPE-19 cells, 4 preselected siRNA duplexes, each targeting 
different sequences of  the human IL-33 gene, were utilized. The effectiveness of  siRNA knockdown (KD) 
was confirmed at the protein and mRNA levels (Figure 4, A and B). Next, we examined the bioenergetic 
status using extracellular flux analysis. Mitochondrial stress analysis identified reduced maximal respiration 
compared with the scrambled siRNA, while no changes were observed in basal respiration (Figure 4, C–E). 
A glycolysis stress test identified increased glycolysis following IL-33 KD (Figure 4, F and G). The increased 
glycolysis observed with IL-33 depletion was confirmed by increased mRNA expression of  key glycolytic 
enzymes lactate dehydrogenase A (LDHA) and GAPDH and a decrease in the key TCA enzyme PC (Figure 
4H). Gene expression correlated to the protein expression of  targets PKM2, GLUT1, and PC (Figure 4, I 
and J). The decreased OCR/ECAR ratio confirmed the increased aerobic glycolysis compared with mito-
chondrial activity (Supplemental Figure 9A). The addition of  rhIL-33 to the IL-33KD cells was unable to 
recompense impaired mitochondrial function significantly (Figure 4K), indicating that it is mainly intrinsic 
IL-33 that regulates the metabolic responses we observed.
Given the marked reduction in mitochondrial metabolism in the absence of  IL-33, we utilized trans-
mission electron microscopy to identify any visible structural changes in IL-33KD RPE mitochondria. 
Compared with a scrambled siRNA, IL-33KD mitochondria appeared larger and more fragmented (Figure 
4L). Image analysis of  mitochondrial samples showed that mitochondrial diameter and area were increased 
with IL-33 siRNA and confirmed that a greater percentage of  mitochondria were of  a fragmented pheno-
type (Supplemental Figure 9B). The fragmented mitochondrial phenotype observed in the IL-33KD group 
was reminiscent of  previously published data in IL-15 T memory cells, whereby mitochondrial fission 
promoted an increased glycolytic capacity (27).
Bioenergetic analysis of  IL-33–/– primary RPE. To investigate further the role of  intrinsic IL-33, we per-
formed a bioenergetic analysis of  primary RPE derived from Il33–/– mice. Using a mitochondrial stress 
test, we observed that in comparison with WT, Il33–/– mice had reduced maximal respiration and spare 
respiratory capacity (Figure 5, A and B). No significant changes were observed in basal respiration or 
ATP production (Figure 5A). Like IL-33KD ARPE-19 cells, we observed that primary Il33–/– RPE had 
increased glycolysis yet lacked glycolytic reserve measured after oligomycin treatment (Figure 5, C and 
D). There was no significant effect on the OCR/ECAR ratio (Figure 5E). Together, these results suggest 
that in the absence of  IL-33 the relative contribution of  glycolysis to ATP production compared with 
OXPHOS is greater. The addition of  rmIL-33 to primary Il33–/– RPE was unable to recompense impaired 
mitochondrial function (Figure 5, F and G).
Further supporting a nuclear role for IL-33, we observed that primary RPE derived from Il1rl1–/– 
mice lacked any metabolic phenotype (Supplemental Figure 10). This excluded the possibility that met-
abolic alterations could have been attributed to lack of  IL-33 release and autocrine/paracrine signaling 
through cognate receptor ST2.
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Figure 4. IL-33 is essential for the maintenance of mitochondrial respiration in RPE. (A) Immunoblot of IL-33 following transfection of ARPE-19 with IL-33 
siRNA or scrambled siRNA (n = 5). (B) Gene expression of IL33 following transfection of ARPE-19 with IL-33 siRNA or scrambled siRNA (n = 3). (C) Mitochon-
drial stress test following transfection of ARPE-19 with IL-33 siRNA or scrambled siRNA; XF injections were oligomycin (1 μM), FCCP (0.5 μM), and rotenone/
antimycin A (1 μM) (n = 4). (D and E) Parameters calculated from C (n = 4). (F) Representative glycolysis stress test following transfection of ARPE-19 with 
IL-33 siRNA or scrambled siRNA; XF injections were glucose (10 mM), oligomycin (1 μM), and 2-deoxyglucose (100 mM) (n = 4). (G) Parameter calculated from 
F (n = 4). (H) ARPE-19 were transfected with IL-33 siRNA or scrambled siRNA; RT-PCR was used to determine the relative gene expression of targets involved 
in glycolysis or the TCA cycle (n = 3). (I and J) ARPE-19 cells were transfected with either IL-33 siRNA or scrambled siRNA; immunoblot analysis demonstrating 
expression of PKM2, GLUT1, and PC (n = 3). (K) Following transfection of ARPE-19 with IL-33 siRNA or scrambled siRNA, cells were treated with rhIL-33 for 24 
hours; spare respiratory capacity was analyzed using a mitochondrial stress test; XF injections were oligomycin (1 μM), FCCP (0.5 μM) and rotenone/antimycin 
A (1 μM) (n = 3). (L) Representative transmission electron microscopy of ARPE-19 cells transfected with IL-33 siRNA or scrambled siRNA; original magnifica-
tion, ×4500. Data are expressed as means ± SD from at least 3 independent experiments. (C–G) Represent the biological repeats from 3 independent experi-
ments (n = 3); each biological repeat is the mean of 2 technical repeats (2 seahorse wells per experiment). (K) Represents the biological repeats from 3 inde-
pendent experiments (n = 3); each biological repeat is either the mean of 2 technical repeats or a single technical repeat (1 or 2 seahorse wells per experiment). 
(A) Unpaired Student’s t test; *P < 0.05, ***P < 0.001. (B, E, and G–K) One-way ANOVA with Dunnett’s multiple comparisons test; *P < 0.05, **P < 0.01.
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We utilized transmission electron microscopy to identify any visible structural changes in Il33–/– RPE 
mitochondria. Compared with WT, Il33–/– mitochondria appeared smaller and more irregular in size (Fig-
ure 5H). Image analysis of  mitochondrial samples showed that mitochondrial diameter was decreased in 
Il33–/– (Supplemental Figure 11A). No significant changes were observed in mitochondrial area, but there 
was increased mitochondrial number/field in the Il33–/– group (Supplemental Figure 11, B and C). In con-
trast to the data presented from IL-33 loss in human cells, image analysis identified an increase in “short 
tubular” mitochondria in the Il33–/– group (Supplemental Figure 11D).
Role of  nuclear IL-33 in mitochondrial metabolism. Following the identification of  metabolic perturbations 
associated with IL-33 absence in vitro and ex vivo, we examined whether increased IL-33 expression in the 
RPE would have an adverse impact on cell metabolism. Using a CRISPR/Cas9 activation plasmid, the 
expression of  the human IL-33 gene was observed to be upregulated in ARPE-19 cells. The effectiveness 
of  CRISPR/Cas9-mediated overexpression of  IL-33 was confirmed both at the RNA and protein level in 
whole cell lysates (Figure 6, A and B). Because IL-33 functions as a dual-function cytokine, residing within 
the nucleus and acting extracellularly (10), it was necessary to identify the subcellular location of  IL-33 
Figure 5. Bioenergetic analysis of Il-33–/– primary RPE. (A) Mitochondrial stress test of WT and Il33–/– primary murine RPE; XF injections were oligomycin (1 μM), 
FCCP (0.5 μM), and rotenone/antimycin A (1 μM) (n = 4). (B) Parameters calculated from A (as detailed in Results) (n = 4). (C) Glycolysis stress test of WT and 
Il33–/– primary murine RPE; XF injections were glucose (10 mM), oligomycin (1 μM), and 2-deoxyglucose (100 mM) (n = 2). (D) Parameters calculated from C (as 
detailed in Methods) (n = 2). (E) OCR/ECAR ratio of WT and Il33–/– primary murine RPE (n = 4). (F) Primary murine RPE cells were isolated from mice both WT 
and Il33–/– mice and treated for 24 hours with rmIL-33; a mitochondrial stress test was used to assess mitochondrial function; XF injections were oligomycin (1 
μM), FCCP (0.5 μM), and rotenone/antimycin A (1 μM) (n = 2). (G) Parameters calculated from F (as detailed in Methods) (n = 4). (H) Representative transmission 
electron microscopy of RPE from WT and Il33–/– mice. Original magnification, ×9300. (A, B, and E) Represent the biological repeats from 4 independent experi-
ments (n = 4); each biological repeat is either the mean of 2 technical repeats or a single technical repeat (1 or 2 seahorse wells per experiment). (C, D, F, and G) 
Represent the biological repeats from 2 independent experiments (n = 2); each biological repeat is either the mean of 2 technical repeats or a single technical 
repeat (1 or 2 seahorse wells per experiment). (A, B, and E) Represent data from 8 eyes (4 mice) per group. (C, D, F, and G) Represent data from 4 eyes (2 mice) 
per group. (A and B) Unpaired Student’s t test; *P < 0.05, **P < 0.01. (F and G) One-way ANOVA with Dunnett’s multiple comparisons test; *P < 0.05.
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Figure 6. Role of nuclear IL-33 in mitochondrial metabolism. (A) Gene expression of IL33 following transfection of ARPE-19 with either an IL-33 activation plasmid 
or scrambled gRNA activation plasmid (n = 3). (B) Representative immunoblot of IL-33 expression in ARPE-19 transfected with either an IL-33 activation plasmid 
or scrambled gRNA activation plasmid (n = 3). (C) ARPE-19 were transfected with either an IL-33 activation plasmid or scrambled guide RNA (gRNA) activation 
plasmid; cell lysates were split into nuclear or cytoplasmic fractions, and Western blotting was used to determine the subcellular location of IL-33 (n = 2). (D) 
Mitochondrial stress test following transfection of ARPE-19 with either an IL-33 activation plasmid or scrambled gRNA activation plasmid; XF injections were 
oligomycin (1 μM), FCCP (0.5 μM), and rotenone/antimycin A (1 μM) (n = 3). (E) Parameters calculated from D (as detailed in Methods) (n = 3). (F) Glycolysis stress 
test following transfection of ARPE-19 with either an IL-33 activation plasmid or scrambled gRNA activation plasmid; XF injections were oligomycin (1 μM), FCCP 
(0.5 μM), and rotenone/antimycin A (1 μM) (n = 3). (G) Parameters calculated from F (as detailed in Methods) (n = 3). (H) ARPE-19 were transfected with either an 
IL-33 activation plasmid or scrambled gRNA activation plasmid; RT-PCR was used to determine the relative gene expression of targets involved in glycolysis or the 
TCA cycle (n = 3). (I and J) ARPE-19 were transfected with either an IL-33 activation plasmid or scrambled gRNA activation plasmid; expression of PKM2, GLUT1, 
and PC (n = 3) was determined by immunoblot. (K) Representative transmission electron microscopy of ARPE-19 cells transfected with an IL-33 activation plasmid 
or scrambled gRNA activation plasmid. Original magnification, ×4500. Data are expressed as means ± SD from at least 3 independent experiments. (D–G) Repre-
sent the biological repeats from 3 independent experiments (n = 3); each biological repeat is the mean of 2 technical repeats (2 seahorse wells per experiment). (C) 
Represents 2 independent immunoblots. One-way ANOVA with Dunnett’s multiple comparisons test; *P < 0.05, **P < 0.01, ***P < 0.001.
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following overexpression. Increased IL-33 was observed in the nuclear subcellular fraction (Figure 6C). A 
mitochondrial stress test was used to identify changes in OXPHOS parameters associated with IL-33 over-
expression, and this showed increased maximal (FCCP-induced) respiration rates (Figure 6, D and E). Glu-
cose-starved cells were subjected to a glycolysis stress test to identify changes in glycolytic parameters, and 
IL-33 overexpression was found to significantly increase glycolytic metabolism (Figure 6, F and G). This 
was accompanied by increased gene expression of  glycolytic and TCA cycle enzymes (Figure 6H). Protein 
expression of  GLUT1, PC, and PKM2 was confirmed at the protein level (Figure 6, I and J). We finally 
confirmed alterations to mitochondrial function were accompanied by structural alterations. Image analysis 
indicated that mitochondria in the IL-33 overexpression group formed long elongated tubules (Figure 6K 
and Supplemental Figure 12), a structural phenotype associated with increased OXPHOS in T cells (27).
Nuclear IL-33 promotes oxidative glucose metabolism. Because we observed an increase in ECAR (Figure 
4, F and G) and extracellular lactate (Supplemental Figure 13A) in the absence of  IL-33, we investigated 
whether IL-33 might regulate pyruvate import into the TCA cycle. Pyruvate enters the mitochondria 
through the mitochondrial pyruvate carrier complex (MPC) consisting of  components MPC1/2 (28). 
Overexpression of  IL-33 led to increased MPC1 expression, at mRNA and protein levels, but had no sig-
nificant effect on MPC2 expression (Figure 7, A and B). IL-33 KD reduced the expression of  both MPC 
components at the gene and protein levels (Figure 7, C and D). Hence, we performed a modified mito-
chondrial stress test with the additional injection of  the MPC inhibitor UK5099 to assess the contribution 
of  aerobic glucose metabolism to total OCR. In ARPE-19 cells with IL-33 overexpression, the increased 
maximal respiration was largely due to increased pyruvate-dependent respiration (Figure 7, E and F). 
When a similar experiment was performed on IL-33 siRNA cells, it was observed that pyruvate-dependent 
respiration had a significantly reduced contribution to maximal OCR (Figure 7, G and H).
To assess if  pyruvate metabolism was the only component affected by the altered expression of  IL-33, 
or if  other metabolic pathways feeding into the TCA cycle were involved, a similar experiment was conduct-
ed to assess fatty acid oxidation (FAO). Etomoxir treatment after mitochondrial uncoupling significantly 
reduced the OCR; however, between control plasmid and IL-33 plasmid groups, this reduction was not 
significant (Supplemental Figure 13, D and E). With IL-33 loss, we observed that FAO was significantly 
increased (Supplemental Figure 13, F and G), suggesting that FAO is upregulated in the absence of  IL-33 to 
compensate for defects in pyruvate metabolism.
SITA with [U-13C]-glucose was conducted to further assess how IL-33 altered glucose metabolism in RPE. 
In ARPE-19 cells with IL-33 overexpression, C13 labeling indicated increased glycolytic flux (Supplemental 
Figure 14A). No significant changes were observed in glycolysis “endpoint” metabolites pyruvate or lactate 
(Supplemental Figure 14A); however, substantial increases in C13 enrichment were observed in TCA metabo-
lites (Figure 7I), indicating that glucose-derived TCA cycle activity was upregulated with IL-33 overexpression. 
In contrast, ARPE-19 cells with IL-33 KD had a significant increase in the abundance of C13 lactate (Supple-
mental Figure 14B) and decreased C13 enrichment in malate, citrate, and succinate (Figure 7J).
Overexpression of IL-33 led to an increase in the fully labeled citrate mass isotopolog (M+6) (Figure 7K). 
This pattern will occur in citrate when both oxaloacetate and malate are derived from glucose. Increased M+4 
aspartate (Supplemental Figure 14C) and malate (Figure 7L) indicate the increased TCA cycling, which occurs 
with IL-33 overexpression. Labeling patterns using C13-labeled glucose then highlighted differential flux from 
glycolysis and pyruvate input into the TCA cycle. Glucose-derived pyruvate can enter the TCA cycle through 
PDH or PC (Supplemental Figure 14D). The citrate M+2/pyruvate M+3 ratio can serve as a surrogate for 
PDH activity, while the citrate M+3/pyruvate M+3 ratio is used as a surrogate of PC activity (29). IL-33 KD 
significantly reduced the citrate M+3/pyruvate M+3 (Supplemental Figure 14F) ratio, suggesting a decrease 
in the activity of the PC complex. Although no significant changes were observed in the citrate M+3/pyruvate 
M+3 ratio with IL-33 overexpression (Supplemental Figure 14G), there was a significant increase in the citrate 
M+2/pyruvate M+3 ratio (Figure 7N), suggesting that PDH activity was augmented with IL-33 plasmid treat-
ment. Increased PDH activity was supported by reduced PDH E1 phosphorylation status (Figure 7M).
Glutamate labeling was unaffected by IL-33 overexpression (Supplemental Figure 15, A and B). How-
ever, we show that IL-33 knockdown reduced derived C13 labeling of  the M+2 mass isotopolog in glu-
tamate pools (Supplemental Figure 15, C and D). We found no observable C13 labeling detected in α- 
ketoglutarate pools (Supplemental Figure 15, E–H). The decrease in unlabeled α-ketoglutarate observed with 
IL-33 overexpression (Supplemental Figure 15E) suggests that the glutamine metabolism is likely reduced 
as increased glucose-derived carbon is used to support the TCA cycle. The increase in unlabeled glutamate 
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and α-ketoglutarate (Supplemental Figure 15G) suggest that glutamine-derived carbon may support the TCA 
cycle when glucose metabolism is impaired.
Taken together these results indicate that nuclear IL-33 is a critical regulator of  pyruvate oxidative metab-
olism in the RPE. When overexpressed, there is increased glycolytic flux into the TCA cycle most likely 
through increased MPC and PDH activity. The absence of  IL-33 reduces the oxidative catabolism of glucose, 
and as pyruvate is “redirected” to lactate, FAO appears to support the TCA cycle.
Figure 7. Nuclear IL-33 promotes oxidative glucose metabolism. (A and B) ARPE-19 were transfected with either an IL-33 activation plasmid or scrambled 
gRNA activation plasmid; (A) RNA was extracted, and RT-PCR was used to determine the expression of MPC1 and MPC2 (n = 3); (B) protein was extracted 
and Western blot analysis was used to determine the expression of MPC1 and MPC2 (n = 3). (C and D) ARPE-19 were transfected with either an IL-33 siRNA 
or scrambled siRNA; (C) RNA was extracted, and RT-PCR was used to determine the expression of MPC1 and MPC2 (n = 3); (D) protein was extracted and 
Western blot analysis was used to determine the expression of MPC1 and MPC2 (n = 3). (E) Modified mitochondrial stress test following transfection of 
ARPE-19 with either an IL-33 activation plasmid or scrambled gRNA activation plasmid; XF injections were oligomycin (1 μM), FCCP (0.5 μM), UK5099 (5 μM), 
and rotenone/antimycin A (1 μM) (n = 3). (F) Parameter calculated from E (as detailed in Methods) (n = 3). (G) Modified mitochondrial stress test following 
transfection of ARPE-19 with either an IL-33 siRNA or scrambled siRNA; XF injections were oligomycin (1 μM), FCCP (0.5 μM), UK5099 (5 μM), and rotenone/
antimycin A (1 μM) (n = 3). (H) Parameter calculated from G (as detailed in Methods) (n = 3). (I) Uniformly labeled C13-glucose incorporation into ARPE-19 TCA 
cycle metabolites following transfection with either an IL-33 activation plasmid or a scrambled gRNA activation plasmid control; relative abundance of C13 and 
C12 including succinate, fumarate, malate, and citrate (n = 3). (J) Uniformly labeled C13-glucose incorporation into ARPE-19 TCA cycle metabolites following 
transfection with either an IL-33 siRNA or scrambled siRNA control (n = 3). Relative abundance of C13 and C12 including succinate, fumarate, malate, and 
citrate (n = 3). (K and L) Mass isotopolog distributions (MIDs) of ARPE-19 TCA cycle intermediates (K) M+6 citrate and (L) M+4 malate, following transfection 
with either an IL-33 activation plasmid or a scrambled gRNA activation plasmid (n = 3). (M) ARPE-19 were transfected with either an IL-33 activation plasmid/
scrambled gRNA activation plasmid or an IL-33 siRNA/scrambled siRNA; Western blot analysis was used to determine the phosphorylation status of PDH (n 
= 3). (N) Citrate M+3/pyruvate M+3 ratio in ARPE-19 transfected with either an IL-33 activation plasmid or scrambled gRNA activation plasmid (n = 3). Data 
are expressed as means ± SD from at least 3 independent experiments. (E–H) Represent the biological repeats from 3 independent experiments (n = 3); each 
biological repeat is the mean of 3 technical repeats (3 seahorse wells per experiment). Unpaired Student’s t test; *P < 0.05, **P < 0.01, ***P < 0.001.
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Discussion
All cells must be able to maintain their energetic resources to survive when quiescent and upon stress. The RPE 
provides an excellent model system to study basic cellular metabolism due to its active mitochondrial capacity, 
which maintains retinal homeostasis. RPE stress and metabolic alterations including mitochondrial dysfunc-
tion have been demonstrated to be implicated in retinal diseases (6, 30). However, the causal link between 
stress, metabolic alterations, and retinal degeneration remains unclear. In this study, we demonstrate that in 
response to stress, intrinsic cellular immune responses dependent on IL-33 act as a checkpoint for metabolic 
regulation. Control of this metabolic checkpoint means that the RPE can regulate metabolism for rapid energy 
production while ensuring the maintenance of mitochondrial health. We show here that the innate immune 
activation of the RPE through TLR signaling is supported by a distinct metabolic profile dependent on AMPK. 
We find that IL-33 signaling leads to broad transcriptional changes in metabolic genes, which leads to increased 
metabolic flux through glycolysis and the TCA cycle. Moreover, we provide evidence for a potentially novel 
role of intracellular IL-33 as a regulator of RPE metabolism. IL-33 loss increases aerobic glycolysis at the 
expense of oxidative glucose catabolism. Cells overexpressing IL-33 display increased expression of MPC1 
while activating PDH (through dephosphorylation) to facilitate increased pyruvate flux into the TCA cycle.
The concept of a metabolic “retinal ecosystem” was recently introduced by Hurley et al. (3). They propose 
that energy homeostasis in the retina and RPE relies on a complex and specialized metabolic interplay between 
distinct cells, which has implications for retinal diseases (3). This study suggests that dysfunctional mitochon-
drial activity, acquired with age, restricts the concentration of glucose able to reach the photoreceptors and 
consequently reduces the lactate available to the RPE as a fuel source. This increased reliance on glycolysis may 
upset the metabolic ecosystem and lead to photoreceptor death. Our data support the proposal that AMPK, a 
central mediator of the bioenergetic response to innate immune stress, maintains energetic homeostasis in the 
RPE by increasing mitochondrial ATP production. We observed that a stressor, LPS stimulation of the RPE, 
inactivated AMPK. This elicited a metabolic shift toward aerobic glycolysis for ATP production, consistent 
with results observed in other immune cells, dendritic cells, and macrophages (22, 31). Interestingly, our data 
also provide evidence that TLR3 signaling in the RPE (a mechanism leading to retinal degeneration, ref. 32) 
is accompanied by the late activation of AMPK and increases in both glycolysis and OXPHOS. These data 
differ from results observed in dendritic cell populations whereby poly(I:C) stimulation drives increased aerobic 
glycolysis and a decrease in OXPHOS (33, 34), highlighting distinct properties of the RPE. Unlike AMPK, 
mTOR promotes catabolic and proliferative signaling and controls processes such as protein synthesis, metab-
olism, and cell growth that are essential for activated inflammatory cells (35). The activation of AMPK and 
mTOR alongside the increases in glycolysis and OXPHOS we observed following TLR stimulation in RPE 
supports the concept of a metabolic ecosystem essential for photoreceptor and neuronal function.
mtDNA can mediate expression levels of  nuclear genes related to complement, inflammation, and apop-
tosis (17). Studies using cybrid RPE cells with representative mtDNA haplotypes demonstrated that different 
mtDNA variants exhibit a difference in ATP levels, lactate production, and metabolic (glycolytic) enzymes’ 
expression, which further dictates altered expression of  nuclear encoded genes in complement, innate immu-
nity, apoptosis, and proinflammatory signaling pathways (17). Our previous work demonstrated that the 
RPE responds to TLR agonists by increasing expression of  IL-33. IL-33 is a nuclear cytokine whose expres-
sion correlates with mtDNA content in the RPE (8). Therefore, there are contemporaneous changes in RPE 
metabolism and expression of  IL-33 when mtDNA content changes. We propose that IL-33 acts as a signal 
in the RPE to adapt or maintain mitochondrial metabolism. Consistent with prior reports on cancer cells 
(36) and fibroblasts (37), we have identified that IL-33/ST2 signaling is accompanied by increased metabolic 
(particularly glycolytic) activity. In addition, we found that exogenous IL-33 protects RPE cells against the 
noxious effects of  oxidative stress. IL-33 release is regulated by oxidative stress and antioxidants within the 
airway epithelium (38). It is reported to reduce ROS production in fibroblasts (39) and directly enhance the 
activity of  superoxide dismutase in cardiomyocytes (40). However, the data presented here demonstrate no 
change in antioxidant enzyme expression but rather an increase in metabolic flux and mitochondrial activity.
Our findings imply that IL-33 is essential for supporting mitochondrial respiration. We found that mice lack-
ing IL-33 have abnormal mitochondrial morphologies. Upon subsequent in vitro investigation, we observed that 
endogenous IL-33 loss increases aerobic glycolysis as identified by increased lactate production from glucose. 
This increased reliance on glycolysis may therefore upset the metabolic ecosystem and lead to RPE dysfunction. 
This is consistent with observations in adipose tissue whereby isolated mitochondria from Il33–/– mice exhibited 
profound respiratory defects, including reduced OXPHOS, and enzymatic activity of electron transport chain 
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complexes II and IV (18). The same study identified an increased expression of genes involved in the catabolism 
of fatty acids, glucose, and amino acids in Il33–/– adipose tissue, suggesting a similar compensatory mechanism 
in the face of reduced mitochondrial function (18). This highlights that IL-33 can have common roles across 
systems, and our data on its role in retinal metabolism can be extrapolated to other tissues and diseases.
The understanding of  IL-33 has developed beyond the primary implications in the induction of  Th2 
immune responses to that of  a cytokine with a broader activity in Th1 immunity and regulatory responses. In 
allergic and respiratory diseases, IL-33 activates type 2 innate lymphoid cells that elicit eosinophil recruitment 
and Th2 differentiation (41, 42). The proinflammatory role is supported by correlation of  serum IL-33 with 
disease severity in atopic dermatitis (43) and through disease attenuation with IL-33 inhibition in murine 
allergic asthma (44). IL-33 exacerbates disease progression in rheumatoid arthritis models associated with 
proinflammatory cytokine production, mast cell degranulation, and neutrophil recruitment (45, 46). Contrari-
ly, treatment with IL-33 reduces murine atherosclerosis development (16), and IL-33 polarizes  macrophages 
(M2 phenotype), conferring protection against obesity and inflammation while improving glucose regulation.
Multiple lines of evidence suggest that increased aerobic glycolysis with IL-33 loss in the RPE occurs at the 
expense of oxidative glucose catabolism, as IL-33 impairs pyruvate import into the mitochondria through the 
MPC complex. Genetic support for this was obtained from IL-33KD RPE, where we found reduced expres-
sion of both MPC1 and MPC2 (Figure 7), which facilitate the transport of pyruvate into the mitochondria 
(47). Furthermore, cells overexpressing IL-33 displayed reduced aerobic glycolysis as mitochondrial activity 
was increased (Figure 6). The increased expression of MPC complex components and activity of PDH was 
accompanied by an increased consumption and oxidation of glucose within the TCA cycle. The increased 
spare respiratory capacity was found to be attributed to pyruvate import following the use of an MPC-specific 
inhibitor, UK5099 (48) (Figure 7E). We found that IL-33 is a key mediator of transcriptional changes to glyco-
lytic and TCA cycle genes, which either drive the RPE toward aerobic glycolysis or mitochondrial catabolism 
of pyruvate in its absence or presence, respectively. Altered MPC1/2 expression results in significant metabolic 
disorders and has been previously shown to contribute to the Warburg effect in cancer cells (49).
While our data have uncovered a role for IL-33 in mitochondrial respiration in RPE, a key question 
that emerges from our work is how IL-33 regulates expression of  MPC1/2 in RPE to facilitate the trans-
port of  pyruvate. The protective effect of  exogenous rhIL-33 on RPE against oxidative stress was associated 
with increased metabolic flux and mitochondrial activity. In the future, generation of  cell- and tissue-specific 
knockouts of  IL-33 will be necessary to pinpoint the critical cell types that release IL-33 and the targets on 
which it acts to regulate the retinal metabolic ecosystem.
In conclusion, we have demonstrated that IL-33 constitutes a key metabolic checkpoint that antagonizes 
the Warburg effect to ensure the functional stability of the RPE. The identification of IL-33 as a key regulator 
of mitochondrial metabolism suggests roles for this cytokine that go beyond its extracellular “alarmin” activi-
ties. For example, when RPE is under stress, IL-33 contributes to minimize the effects of oxidative damage to 
the RPE and bolster mitochondrial metabolism. IL-33 exerts control over mitochondrial respiration in RPE 
by facilitating pyruvate import into mitochondria via upregulation of MPC expression and may be associated 
with the capacity of RPE to maintain homeostasis. Therefore, as well as identifying a molecular pathway for 
activation of mitochondrial respiration in RPE, our results demonstrate that intrinsic cellular IL-33 acts as a 
metabolic regulator exerting profound effects on retinal metabolism.
Methods
Cell lines
Immortalized human retinal pigment epithelium (ARPE-19) and human Müller glial Moorfields/Institute of  
Ophthalmology-Müller 1 (MIO-M1) cell lines were cultured in DMEM (4.5 mg/L) supplemented with 10% 
heat-inactivated FBS, 2 mM l-glutamine, 1 mM sodium-pyruvate, 0.5 μM 2-mercaptoethanol, 100 U/mL pen-
icillin, and 100 μg/mL streptomycin. All cell lines were maintained at 37°C and were routinely screened for 
mycoplasma contamination. The human MIO-M1 was purchased from the UCL Business PLC. The ARPE-
19 cell line is a spontaneously arising cell line derived from human RPE (ATCC number CRL-2302, ref. 50).
Primary cells
C57BL/6J mice were purchased from Charles River Laboratories. All mice were maintained in the animal 
house facilities of  the University of  Bristol, according to Home Office Regulations. Animal husbandry and 
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procedures complied with the Association for Research in Vision and Ophthalmology (ARVO) statement for 
the use of  animals in ophthalmic and vision research. Il33–/– mice were generated as described earlier (51) at 
the animal house facilities of  Trinity College Dublin and sent to the animal house facilities of  the University 
of  Bristol when required. IL-1RL1 (ST2) knockout (Il1rl1–/–) C57BL/6 mice (backcrossed for 10 generations) 
were provided by C. Emanueli (School of  Clinical Sciences, Bristol Heart Institute, University of  Bristol, 
Bristol, United Kingdom) and were generated as described earlier (46).
Primary murine RPE cells were obtained as described earlier (52). Eyes were enucleated and incubated 
at 37°C in hyaluronidase for 45 minutes and in HBSS with calcium, magnesium, and 10 mM HEPES for a 
further 30 minutes. An incision was made beneath the ora serrata to remove the iris epithelium and cornea. 
The neural retina and the attachment to the optic nerve were removed. Eyecups were incubated at 37°C in 
trypsin EDTA for 45 minutes. Eyecups were then transferred into HBSS with 20% FBS and shaken gently to 
allow the RPE to detach. The RPE sheets were incubated at 37°C in 1 mL trypsin EDTA for 1 minute; 9 mL 
primary RPE media was then added, followed by centrifugation at 340g for 2 minutes at room temperature 
and supernatant removal. The resulting RPE cells were resuspended in 200 μL primary RPE media and 
homogenously mixed using a p200 pipette. Cells were used within 10 days of  extraction. Cells were cul-
tured in α-MEM, containing 1% N1 supplement, 1% glutamine-1% penicillin-streptomycin, 1% nonessential 
amino acid solution, 5% heat-inactivated FBS, 20 μg/L hydrocortisone, 250 mg/L taurine, and 13 ng/L 
triiodo-thyronin. Purity was assessed by immunoblotting for RPE-specific protein RPE65 and rhodopsin 
contamination from the neurosensory retina.
BMMCs were generated from C57BL/6 as previously described (53). Legs were taken from mice 
and the bones were cut at the end using angled scissors to expose the red marrow. Using a syringe and a 
23-gauge needle, DMEM was flushed through the bone. DMEM containing the cell suspension was spun 
at 14,000g for 5 minutes in a centrifuge cooled to 4°C. The resulting cell pellet was resuspended in DMEM 
containing IL-3 (10 ng/mL) and dispensed into a cell culture flask. The cell suspension was cultured for 5 
weeks to allow the generation of  a mast cell population. Prior to functional assays, mast cells were sorted 
into a viable population using a MACS dead cell removal kit, and the purity was assessed by FACS based 
on CD117 and CD45 cell surface marker expression.
Cell culture
Cells were seeded at a density of  100,000 per well of  a 24-well plate and were exposed to different inflam-
matory stimuli: poly(I:C) (10 μg/mL), LPS (1 μg/mL), and IL-33 (1–100 ng/mL, as detailed in the results). 
Oxidative stress was induced by addition of  hydrogen peroxide (1 mM). AMPK activity was modulated by 
activator AICAR (1 mM) and inhibitor compound C (40 μM) (Tocris Biosciences, Bio-Techne). Unstimu-
lated controls and vehicle controls (DMSO) were always included.
Western blot
Following treatment, protein extraction was performed using Cell-Lytic-M with the addition of  Protease/
Phosphatase Inhibitor Cocktail (MilliporeSigma). A commercial (Active Motif) nuclear extraction kit was 
used for the preparation of  nuclear and cytoplasmic extracts as per the manufacturer’s instructions. Cells 
were washed twice with 1 mL of  ice-cold PBS/phosphatase inhibitors, and 0.3 mL of  ice-cold PBS/phos-
phatase inhibitors was added. Cells were removed from the cell culture plate by gentle scraping. Samples 
were pooled from 2 wells of  a 24-well plate. The resulting cell suspension was centrifuged for 5 minutes at 
200g in a centrifuge cooled to 4°C. The supernatant was removed and the pellet kept on ice prior to resuspen-
sion in 100 μL hypotonic buffer containing 5% (v/v) detergent. The resulting cell suspension was centrifuged 
for 30 seconds at 14,000g in a centrifuge cooled to 4°C. The supernatant was removed as the cytoplasmic 
fraction. The remaining pellet was resuspended in 25 μL of  complete lysis buffer and incubated for 30 min-
utes on ice on a rocking platform. The resulting cell suspension was centrifuged for 10 minutes at 14,000g in 
a centrifuge cooled to 4°C. The supernatant was removed as the nuclear fraction.
Protein concentration was assessed using a BCA assay kit (Thermo Fisher Scientific). A total of  15 
μg of  protein was separated by SDS-PAGE, transferred to a PVDF membrane, and blocked in 5% milk/
TBS/Tween-20. Immunoblotting was performed by the addition of  a primary antibody against the protein 
of  interest (antibody details provided in Supplemental Table 1). Proteins were detected with a polyclonal 
HRP-conjugated secondary antibody and visualized using chemiluminescent detection. Relative protein 
expression was calculated by normalization to β-actin, β-tubulin, or histone 3.
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RT-PCR
RNA was isolated from cells using the RNeasy extraction kit (QIAGEN). Purity and RNA concentration 
were assessed using a NanoDrop 3000 spectrophotometer (Thermo Fisher Scientific); 1 μg RNA was reverse 
transcribed using a SuperScript III First-Strand Synthesis system (Thermo Fisher Scientific). Resulting 
cDNA was then diluted 1:20 and amplified using SYBR Green reagents in a StepOne Plus detection sys-
tem (Thermo Fisher Scientific). Cycling conditions: heat ramp 95°C for 10 minutes, extension (95°C for 15 
seconds, 60°C for 1 minute) for 45 cycles, melt curve 95°C for 15 seconds, 60°C for 1 minute, 95°C for 15 
seconds. Relative gene expression was calculated by normalization to β-actin. The primer sequences used are 
detailed in Supplemental Table 1.
Genetic modulation of IL-33
Knockdown of  IL-33 from ARPE-19 cells was achieved using the fast-forward transfection technique. Cells 
were seeded at a concentration of  55,000 per well of  a 24-well plate in 0.5 mL of  culture medium with 1% 
FCS and no antibiotics. Cells were incubated for 1 hour at 37°C prior to transfection. The FlexiTube Gene-
Solution (QIAGEN), as a specific mixture of  4 preselected siRNA duplexes, was used to target different 
sequences of  the human IL-33 gene. Each siRNA was diluted in 100 μL of  culture medium without serum 
and antibiotics (final concentration 20 nM each siRNA). HiPerfect transfection reagent (6 μL) was added to 
the siRNA, which was then vortexed and left for 5 minutes. Transfection complex (OriGene) (100 μL) was 
added to the cells and left for 48 hours at 37°C.
For IL-33 overexpression in ARPE-19 cells, a CRISPR/Cas9 activation plasmid was used to upregulate the 
expression of the human IL-33 gene. Cells were seeded at a concentration of 40,000 per well of a 24-well plate 
in 0.5 mL of culture medium with 10% FCS and no antibiotics. Cells were incubated overnight at 37°C prior 
to transfection. Medium was replaced just before transfection. For each transfection, 0.16 μg of plasmid DNA 
was diluted into 25 μL plasmid transfection medium. Separately, 0.833 μL of transfection reagent was diluted in 
25 μL plasmid transfection medium. Both solutions were left for 5 minutes before being combined, mixed, and 
left for a further 30 minutes. Transfection complex (50 μL) was added to the cells and left for 48 hours at 37°C.
Cell viability assays
Cell proliferation was assessed using the colorimetric MTT assay as per the manufacturer’s instructions (Milli-
poreSigma). A total of 10 μL of the 12 mM MTT stock solution in 100 μL of culture medium was added to cells 
and incubated at 37°C for 2 hours. All but 25 μL of medium was aspirated from the wells. DMSO (50 μL) was 
added and incubated 37°C for 30 minutes; the solution was transferred into a 96-well plate. Absorbances were 
read at 540 nm and expressed as a percentage of untreated control.
Cellular cytotoxicity was quantified using an LDH detection kit as per the manufacturer’s instructions. Brief-
ly, 50 μL of cell culture supernatant was transferred to a 96-well plate with 50 μL of the reaction mixture and 
incubated 37°C for 30 minutes. Absorbances were read at 450 nm and expressed as relative to untreated control.
Enzyme-based metabolic assays
Glucose consumption was assessed using a glucose coulometric assay kit as per the manufacturer’s instruc-
tions (Cayman Chemicals). A total of  15 μL of  cell culture supernatant was transferred to a 96-well plate 
with 85 μL of  diluted assay buffer. Then 100 μL of  enzyme buffer was added and incubated at 37°C for 
10 minutes. Absorbances were read at 520 nm. Glucose consumption was calculated by subtracting the 
glucose concentration of  samples from the glucose concentration of  unconditioned media and expressed as 
relative to an untreated control.
Extracellular lactate production was measured using an l-lactate fluorometric assay kit as per the manu-
facturer’s instructions (Cayman Chemicals). A total of  20 μL of cell culture supernatant was transferred to a 
96-well plate with 100 μL diluted assay buffer, 20 μL of cofactor mixture, 40 μL of enzyme mixture, and 20 
μL of fluorometric substrate. The plate was incubated for 20 minutes at room temperature and read using an 
excitation wavelength at 530 nm and an emission wavelength of  590 nm. Lactate production was calculated 
by subtracting the lactate concentration of  samples from the lactate concentration of  unconditioned media 
and expressed as relative to an untreated control.
ATP and ADP measurements were quantified using an ATP/ADP fluorometric assay kit (Cayman 
Chemicals). Cell supernatants were removed and 500 μL of  nucleotide releasing buffer was added to cells. 
A total of  90 μL of  this buffer was transferred to a 96-well plate and background ATP fluorescence was 
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measured. Then 10 μL of  ATP-monitoring enzyme was added and left for 2 minutes at room temperature. 
ATP fluorescence levels were then measured. The fluorescence levels were subsequently measured again 
to give background ADP fluorescence. Then 10 μL of  ADP converting enzyme was added and left for 2 
minutes at room temperature. ADP fluorescence levels were then measured. ATP and ADP levels were 
calculated and expressed as the ATP/ADP ratio. Data are expressed as relative to an untreated control.
ELISA
Cell culture supernatants were analyzed for malonyl CoA using a commercially available ELISA kit 
(CUSABIO).
Extracellular flux analysis
Cell metabolism was assessed using a Seahorse XFp Extracellular Flux Analyzer (Agilent Technologies). 
ARPE-19 and M1-MO were seeded at a density of  30,000 cells per well, 24 hours prior to analysis, with 
further treatments detailed in Results. Cell-Tak (Corning) was used to attach primary RPE and BMMCs at 
a density of  50,000 to the XFp. Real-time measurements of  OCR and ECAR were normalized to total pro-
tein content using a BCA assay. Preoptimized injections specific for each assay were used. Cell Mito Stress 
kit (Agilent Technologies) injections: oligomycin (1 μM), FCCP (0.5 μM), and antimycin A/rotenone (1 
μM). Glycolysis stress injections: glucose (10 mM), oligomycin (1 μM), and 2-deoxyglucose (2-DG) (1 μM). 
Glycolysis rate injections: antimycin A/rotenone (1 μM) and 2-DG (1 μM). UK5099 (5 μM) was used to 
inhibit the mitochondrial pyruvate transporter MPC1. Etomoxir (3 μM) was used to inhibit carnitine pal-
mitoytransferase 1 (CPT1). GSK 2837808A (1 μM) was used to inhibit LDHA. Potassium dichloroacetate 
(25 mM) was used to inhibit PDK1.
XF medium included 25 mM glucose, 1 mM pyruvate, and 2 mM glutamine in minimal DMEM at 
pH 7.4. Metabolic parameters were calculated using the following formulae: OCR/ECAR (first OCR 
measurement)/(first ECAR measurement), proton leak (difference between OCR after oligomycin and 
nonmitochondrial respiration), nonmitochondrial respiration (OCR measurement after antimycin A/
rotenone), basal respiration (difference between OCR before oligomycin and nonmitochondrial respira-
tion), ATP production (difference between basal respiration and proton leak), maximal respiration (differ-
ence between maximum OCR after FCCP injection and nonmitochondrial respiration), spare respiratory 
capacity ([maximal respiration/basal respiration] × 100), glycolysis (difference between maximum ECAR 
before oligomycin and nonglycolytic acidification), glycolytic capacity (difference between maximum 
ECAR after oligomycin and nonglycolytic acidification), glycolytic reserve (difference between glycolytic 
capacity and glycolysis), nonglycolytic acidification (last ECAR measurement before glucose injection), 
basal glycolysis (last glycolytic proton efflux rate [glycoPER] measurement before rotenone/antimycin A), 
compensatory glycolysis (maximum glycoPER measurement after rotenone/antimycin A), mitoOCR/
glycoPER ([(last OCR before rotenone/antimycin A) – (minimum OCR after rotenone/antmycin A)]/
basal glycolysis), percentage PER from glycolysis ([basal glycolysis/basal PER] × 100), MPC-dependent 
respiration (difference between OCR before and after UK5099), and CPT1-dependent respiration (differ-
ence between OCR before and after etomoxir).
Mass spectrometry
Gas chromatography coupled to mass spectrometry was performed using previously detailed methods (54). 
For SITA experiments, ARPE-19 cells were seeded at a concentration of  1,000,000 per well of  a 6-well 
plate in 3 mL of  normal culture medium with 10% FCS and antibiotics and left for 24 hours to reach 
subconfluence before treatment. Cells were washed twice with PBS before pulsing with [U-13C]-glucose 
medium for 2 hours. SITA media contained 10 mM [U-13C]-glucose, 2 mM glutamine, and 10% dialyzed 
FBS. Cells were washed twice with saline and lysed with 0.8 mL methanol, sonicated, and freeze dried 
using a speed vacuum. MIDs were derived using an algorithm developed at McGill University (55). Rela-
tive metabolite levels were normalized to protein content (μg) using a BCA assay.
Electron microscopy
For ex vivo electron microscopy (EM), WT and Il-33–/– mouse eyes were enucleated with the anterior cham-
ber removed and fixed in 2.5% glutaraldehyde in 0.1 M phosphate buffer. Eyes were washed in buffer after 
fixation in osmium tetroxide for 1 hour and en bloc stained with uranyl acetate prior to being dehydrated with 
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ethanol and embedded in Epon resin (TAAB labs). After polymerization the embedded eyes were trimmed 
to remove excess material, revealing the retina and choroid layers. These were sectioned transversely at 0.5 
μm for light microscopy. Suitable areas were selected for transmission electron microscopy, and these were 
sectioned (80 nm thick) and stained with uranyl acetate and lead citrate prior to observation in a Tecnai 12 
microscope. For in vitro EM, cells were grown to subconfluence in 24-well plates and treated as detailed in 
the results. Cells were washed in buffer and fixed in phosphate-buffered glutaraldehyde and postfixed using 
osmium tetroxide in the same buffer. Cells were stained with uranyl acetate and then after ethanol dehydra-
tion were infiltrated with Epon resin mix and polymerized at 60°C for 2 days. Sections were cut at 70–80 nm 
thickness using an Ultracut S ultramicrotome and stained with Reynolds’ lead citrate and uranyl acetate. 
Sections were viewed and images recorded on a Tecnai T12 microscope.
Quantification and statistics
ImageJ. Mitochondrial morphology was manually assessed using ImageJ software (NIH). A scale was set 
by normalizing the pixel distance to the scale provided (nm) on each image (Supplemental Figure 16A). 
Area measurements were calculated by freehand selection around every whole mitochondrion observed 
in each image (Supplemental Figure 16B). Three separate measurements were taken; the mean value was 
used as the area. Diameter measurements were calculated by freehand lines at the largest part of  every 
whole mitochondrion observed in each image (Supplemental Figure 16C). Mitochondrial numbers were 
manually counted in each image, which corresponded to a 4.95 μm2 (ex vivo) or 37 μm2 (in vitro) area of  
the RPE; only whole mitochondria were counted (Supplemental Figure 16D). Mitochondria were manu-
ally characterized into (Supplemental Figure 16D) “short tubular,” (Supplemental Figure 16E) “fragment-
ed,” or (Supplemental Figure 16F) “long tubular” phenotypes.
Seahorse analysis. As the number of  wells used of  a seahorse plate vary between experiment, the number 
of  technical repeats (wells used) is reported in each experiment. The mean of  these technical repeats (wells 
used) was subsequently used to provide the biological repeat for that experiment. If  no technical repeats 
were used (only 1 well per condition), that sole value is used for the biological repeat of  that experiment. 
The reported data are of  biological repeats from at least 3 independent experiments.
Statistics. Data are presented as mean ± SD for technical replicates or mean ± SEM for biological rep-
licates. Statistical analysis was performed using an unpaired 2-tailed Student’s t test or 1-way ANOVA as 
specified for comparison between groups. P < 0.05 was considered significant.
Study approval
All procedures were conducted under the regulation of  the United Kingdom Home Office Animals (Sci-
entific Procedures) Act 1986 and followed the ARVO statement for the use of  animals in ophthalmic and 
vision research. The methods were carried out in accordance with the approved University of  Bristol 
institutional guidelines, and all experimental protocols under Home Office Project Licence 30/3281 were 
approved by the University of  Bristol Ethical Review Group.
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